Analysis of the economic burden associated with comparing biological therapy to traditional conventional therapies for the treatment of moderate-to-severe atopic dermatitis.

Author:

WANG xueling1,LI zhen1,WU Xiaoxiao1,XU hao1,CHEN jialin1,SHI xiaoxuan1,GAO yanqing1,SUN wen1,WEI li1,LIU yun1,LIU hong1,ZHANG furen1

Affiliation:

1. Hospital for Skin Diseases, Shandong First Medical University

Abstract

Abstract Background: Atopic dermatitis (AD) is a chronic, relapsing, and pruritic inflammatory skin disease with a high incidence rate, posing a considerable challenge for patients, society, and the healthcare system due to its chronic nature. In China, there is a scarcity of cost-effectiveness evidence concerning AD treatment. This study aimed to assess the cost-effectiveness of two prevalent treatments for moderate-to-severe AD—traditional conventional therapy (CT) and biological therapy (BT). Methods: A retrospective cohort study involving 97 patients with moderate-to-severe AD was conducted. Data were collected from a public tertiary dermatology hospital in Shandong Province, China. Primary outcome measures included total economic cost and treatment efficacy evaluated using the Severity Scoring of AD (SCORAD) index. The sustained treatment effect over six months was analyzed from a societal perspective. Results: This study included a total of 97 participants, with 47 receiving BT treatment and 50 receiving CT treatment. The entire treatment duration was 6 months, and the endpoint evaluation was the skin SCORAD score of the patients after 6 months of treatment. The average cost per person for BT was ¥28719.23, and for CT it was ¥8020.78. The cost-effectiveness ratio for BT was lower (¥34,609.82), signifying a lower cost per unit of effect gained. Patients utilizing CT incurred an additional expenditure of ¥31,853.56 for each additional unit of effectiveness compared to BT. Additionally, one-way sensitivity analysis underscored the cost of BT and its effectiveness as the most sensitive parameters in the model. Conclusion: BT emerged as the most cost-effective choice in the treatment of moderate-to-severe AD based on cost-effectiveness analysis. This research investment aids decision-makers in determining first-line treatment options for moderate-to-severe AD.

Publisher

Research Square Platform LLC

Reference35 articles.

1. Atopic dermatitis: Current standards of diagnosis and treatment, including the latest methods of management;Fornal R;Postępy Higieny i Medycyny Doświadczalnej,2022

2. The global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study;Tian J;Br J Dermatol,2023

3. Prevalence and risk factors of atopic dermatitis in Chinese adults: a nationwide population-based cross-sectional study;Mao D;Chin Med J,2023

4. Section 1. Diagnosis and assessment of atopic dermatitis Work Group;Eichenfield LF;J Am Acad Dermatologyl,2014

5. Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization;Silverberg JI;Pediatr allergy immunology: official publication Eur Soc Pediatr Allergy Immunol,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3